Maxime Madder

Director: Biologics and Infectious Diseases

Prof Dr Maxime Madder graduated from Ghent University in 1991 as biologist with the specialization biotechnology. Thereafter he was employed at the Institute of Tropical Medicine (ITM) in the Department of Animal Health were he focused on the control of East Coast fever (ECF), a tick-borne diseases affecting cattle. Apart from scientific studies unraveling the ecology of the vectors of ECF, for which he obtained a PhD degree, he also worked on the development of ECF vaccines. In 2013 he became Professor and head of the unit Veterinary Entomology.

Apart from studies on vectors and vector-borne diseases in the tropics, he also dedicated many years on vector-surveillance of endemic and exotic vectors in Europe, focusing on ticks, mosquitoes and midges.
In 2005 he was also appointed, as extra-ordinary Professor at the University of Pretoria in the Department of Veterinary Tropical Diseases were he still supports the department on the level of education and scientific research. During his scientific career, he published almost 100 scientific articles, wrote chapter in several books, was promoter of many MSc and PhD theses and presented his work in scientific meeting (WAAVP, TTP, E-Sove, BSP, etc).

In 2016, Prof Madder left ITM and became Director Biologics and Infectious Diseases at Clinglobal, Mauritius, where he applies his solid scientific and business principles to upscale the overall scientific knowledge of the teams and improve quality and outputs. Key is to engage teams to be more productive by developing and implementing compliant systems and procedures. As a monitor of GCP/GLP studies, quality is closely controlled for both laboratory and field studies.

For any of the activities performed at Clinglobal, the general objective is putting the customer first. Quality, trust and efficacy are essential to build a long-standing partnership with each individual partner. Clinglobal in general adheres strictly to the three R’s principle and especially well-being of its animals. It is also continuously developing new in-vitro models that contribute to the improvement and testing of vaccines against ticks and tick-borne diseases.